Clinical Trial Update: Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202) [Phase 2]

View source ↗

Summary

Phase 2 trial results for T-817MA in mild-to-moderate Alzheimer's disease have been completed with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• T-817MA

Snippet

Sponsor: FUJIFILM Toyama Chemical Co., Ltd. | Conditions: Alzheimer's Disease | Phase 2 | Status: COMPLETED | Results posted: 2018-08-09